138 related articles for article (PubMed ID: 34799137)
1. Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
Matuszewska K; Ten Kortenaar S; Pereira M; Santry LA; Petrik D; Lo KM; Bridle BW; Wootton SK; Lawler J; Petrik J
Gynecol Oncol; 2022 Jan; 164(1):154-169. PubMed ID: 34799137
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.
Russell S; Duquette M; Liu J; Drapkin R; Lawler J; Petrik J
FASEB J; 2015 Feb; 29(2):576-88. PubMed ID: 25395453
[TBL] [Abstract][Full Text] [Related]
3. AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma.
Yu DL; Stegelmeier AA; Chow N; Rghei AD; Matuszewska K; Lawler J; Bridle BW; Petrik JJ; Wootton SK
Cancer Gene Ther; 2020 May; 27(5):356-367. PubMed ID: 31160686
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
Zhang X; Galardi E; Duquette M; Lawler J; Parangi S
Clin Cancer Res; 2005 Aug; 11(15):5622-30. PubMed ID: 16061881
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model.
Zhang X; Galardi E; Duquette M; Delic M; Lawler J; Parangi S
Clin Cancer Res; 2005 Mar; 11(6):2337-44. PubMed ID: 15788685
[TBL] [Abstract][Full Text] [Related]
6. Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Matuszewska K; Santry LA; van Vloten JP; AuYeung AWK; Major PP; Lawler J; Wootton SK; Bridle BW; Petrik J
Clin Cancer Res; 2019 Mar; 25(5):1624-1638. PubMed ID: 30206160
[TBL] [Abstract][Full Text] [Related]
7. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model.
Zhang X; Connolly C; Duquette M; Lawler J; Parangi S
Cancer Lett; 2007 Mar; 247(1):143-9. PubMed ID: 16757110
[TBL] [Abstract][Full Text] [Related]
8. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin.
Zhang X; Xu J; Lawler J; Terwilliger E; Parangi S
Clin Cancer Res; 2007 Jul; 13(13):3968-76. PubMed ID: 17606731
[TBL] [Abstract][Full Text] [Related]
9. AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma.
Stegelmeier AA; Santry LA; Guilleman MM; Matuszewska K; Minott JA; Yates JGE; Stevens BAY; Thomas SP; Vanderkamp S; Hanada K; Pei Y; Rghei AD; van Vloten JP; Pereira M; Thompson B; Major PP; Petrik JJ; Bridle BW; Wootton SK
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203573
[TBL] [Abstract][Full Text] [Related]
10. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.
Greenaway J; Henkin J; Lawler J; Moorehead R; Petrik J
Mol Cancer Ther; 2009 Jan; 8(1):64-74. PubMed ID: 19139114
[TBL] [Abstract][Full Text] [Related]
11. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.
Campbell NE; Greenaway J; Henkin J; Moorehead RA; Petrik J
Neoplasia; 2010 Mar; 12(3):275-83. PubMed ID: 20234821
[TBL] [Abstract][Full Text] [Related]
12. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas.
Choi SH; Tamura K; Khajuria RK; Bhere D; Nesterenko I; Lawler J; Shah K
Mol Ther; 2015 Feb; 23(2):235-43. PubMed ID: 25358253
[TBL] [Abstract][Full Text] [Related]
14. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.
Wang S; Blois A; El Rayes T; Liu JF; Hirsch MS; Gravdal K; Palakurthi S; Bielenberg DR; Akslen LA; Drapkin R; Mittal V; Watnick RS
Sci Transl Med; 2016 Mar; 8(329):329ra34. PubMed ID: 26962158
[TBL] [Abstract][Full Text] [Related]
15. A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR.
Ren B; Song K; Parangi S; Jin T; Ye M; Humphreys R; Duquette M; Zhang X; Benhaga N; Lawler J; Khosravi-Far R
Cancer Res; 2009 May; 69(9):3856-65. PubMed ID: 19366809
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-1 type 1 repeats in a model of inflammatory bowel disease: transcript profile and therapeutic effects.
Lopez-Dee ZP; Chittur SV; Patel B; Stanton R; Wakeley M; Lippert B; Menaker A; Eiche B; Terry R; Gutierrez LS
PLoS One; 2012; 7(4):e34590. PubMed ID: 22509329
[TBL] [Abstract][Full Text] [Related]
17. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Stone RL; Baggerly KA; Armaiz-Pena GN; Kang Y; Sanguino AM; Thanapprapasr D; Dalton HJ; Bottsford-Miller J; Zand B; Akbani R; Diao L; Nick AM; DeGeest K; Lopez-Berestein G; Coleman RL; Lutgendorf S; Sood AK
Cancer Biol Ther; 2014 Jul; 15(7):919-29. PubMed ID: 24755674
[TBL] [Abstract][Full Text] [Related]
18. ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer.
Campbell N; Greenaway J; Henkin J; Petrik J
Mol Cancer Ther; 2011 Oct; 10(10):1876-85. PubMed ID: 21844212
[TBL] [Abstract][Full Text] [Related]
19. Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1.
Zeng Z; Lin C; Zhang MC; Kossinna P; Wang P; Cao D; Wang J; Xu M; Wang X; Li Q; Xu X; Yang H; Zhu S; Liu GR; Xie K; Yang J; Luo Y; Wang Y; Zhang XH; Lin J; Chen H; Liu SL; Liu H
Phytother Res; 2023 Oct; 37(10):4722-4739. PubMed ID: 37443453
[TBL] [Abstract][Full Text] [Related]
20. LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model.
Mehdi S; Macdonald E; Galpin K; Landry DA; Rodriguez G; Vanderhyden B; Bachvarov D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
